Who are Chemotherapy,Gemcitabine based regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemcitabine (GEM), Fludarabine mono, Chemotherapy, gemcitabine, Gemcitabine alone, clofarabine, fludarabine and busulfan, CloFluBu, Pifeltro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chemotherapy-gemcitabine-based-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Chemotherapy,Gemcitabine based regimen — Competitive Intelligence Brief

Chemotherapy,Gemcitabine based regimen (Chemotherapy,Gemcitabine based regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog; antimetabolite chemotherapy. Area: Oncology.

phase 3 Nucleoside analog; antimetabolite chemotherapy Ribonucleotide reductase; DNA polymerase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Chemotherapy,Gemcitabine based regimen (Chemotherapy,Gemcitabine based regimen) — Eye & ENT Hospital of Fudan University. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chemotherapy,Gemcitabine based regimen TARGET	Chemotherapy,Gemcitabine based regimen	Eye & ENT Hospital of Fudan University	phase 3	Nucleoside analog; antimetabolite chemotherapy	Ribonucleotide reductase; DNA polymerase
Gemcitabine (GEM)	Gemcitabine (GEM)	Sun Yat-sen University	marketed	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA polymerase
Fludarabine mono	Fludarabine mono	German CLL Study Group	phase 3	Purine analog antimetabolite	Ribonucleotide reductase; DNA polymerase
Chemotherapy, gemcitabine	Chemotherapy, gemcitabine	University of Erlangen-Nürnberg Medical School	phase 3	Nucleoside analog; antimetabolite chemotherapy	Ribonucleotide reductase; DNA polymerase
Gemcitabine alone	Gemcitabine alone	Intergroupe Francophone de Cancerologie Thoracique	phase 3	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA polymerase
clofarabine, fludarabine and busulfan, CloFluBu	clofarabine, fludarabine and busulfan, CloFluBu	Vastra Gotaland Region	phase 3	Chemotherapy combination (nucleoside analogs + alkylating agent)	DNA synthesis and repair pathways; ribonucleotide reductase; DNA polymerase
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog; antimetabolite chemotherapy class)

Eye & ENT Hospital of Fudan University · 1 drug in this class
University of Erlangen-Nürnberg Medical School · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chemotherapy,Gemcitabine based regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/chemotherapy-gemcitabine-based-regimen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab